<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347604">
  <stage>Registered</stage>
  <submitdate>19/10/2011</submitdate>
  <approvaldate>24/10/2011</approvaldate>
  <actrnumber>ACTRN12611001107910</actrnumber>
  <trial_identification>
    <studytitle>A Pilot Randomized Cross-over Study of Two Mean Arterial Pressure Targets During and Immediately After Cardiac Surgery</studytitle>
    <scientifictitle>A Pilot Randomized Cross-over Study of The Effects of Two Mean Arterial Pressure Targets During and Immediately After Cardiac Surgery on Hepatic Vein Oxygen Saturation.</scientifictitle>
    <utrn>None</utrn>
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>cardiac surgery</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Increase in mean arterial pressure with intravenous noradrenaline infusion. 
Noradrenaline will be infused through a central venous catheter at th enecessary dose to achieve and maintain a MAP 20 mmHg grater than baseline for 30 minutes while the patient is on cardiopulmonary bypass and for 2 hours after the patient is returned to ICU.

The noradrenaline infusion will then be decreased after such period and the patient returned to baseline levels.
This cross over will have no washout period.
After the noradrenaline infusion, patients will then be immediately crossed over to the standard care arm,</interventions>
    <comparator>Standard care.
This involves invasive monitoring of blood pressure, cardiac output and central venous pressure and administration of  drugs and fluids to maintain a mean arterial pressure of 60-70 mmHg. This will occur during cardiopulmonary bypass in the period before and after the intervention.
Standard care will also be delivered after cardiopulmonary bypass in the period after cessation of intervention and will continue as clinically indicated thereafter.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Hepatic vein oxygen saturation.
This is measured by the insertion of curved catehter from the femoral vein guided by X-ray into the hepatic vein.
The catheter can be used to obtain blood form the hepatic vein which is the then taken to a blood gas machine, where arterial blood gases and oxygen saturation can be measured.</outcome>
      <timepoint>each 2 hours of intervention</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Level of cytokines.

The blood levels of interleukin 6, interleukin-10 and tumour necrosis factor will be measured by ELISA techniques in blood obtained form the radial artery cannula and from the hepatic vein cannula.</outcome>
      <timepoint>each 2 hours of intervention</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Open heart cardiac surgery
Ability to insert a hepatic venin cannula
Informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>100</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Inability to insert hepatic vein catheter
Emergency surgery
Severe disorder of coagulation
Lack of informed consent
Jeovah's witness
Pregnancy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Random numbers and sealed envelopes</concealment>
    <sequence>Random number table</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/01/1999</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>12</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Austin Hospital</primarysponsorname>
    <primarysponsoraddress>Austin Hospital
Studley Rd
Heidelberg, Vic 3084</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Austin Hospital Anaesthesia &amp; Intensive Care Trust Fund</fundingname>
      <fundingaddress>Austin Hospital
Studley Rd
Heidelberg, Vic 3084</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Samll pilot cross over study comparing two differen tmean arterial pressures in patient having cardiac surgery</summary>
    <trialwebsite>none</trialwebsite>
    <publication>none</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Austin Hospital Human research Ethics Committee</ethicname>
      <ethicaddress>Austin Hospital
Studley Rd
Heidelberg, Vic 3084</ethicaddress>
      <ethicapprovaldate>1/01/1999</ethicapprovaldate>
      <hrec>H99/00667</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Rinaldo Bellomo</name>
      <address>Austin Hospital
Studley Rd
Heidelberg, Vic 3084</address>
      <phone>+61394965992</phone>
      <fax>+61394963932</fax>
      <email>rinaldo.bellomo@austin.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Rinaldo Bellomo</name>
      <address>Austin Hospital
Studley Rd
Heidelberg, Vic 3084</address>
      <phone>+61394965992</phone>
      <fax>+61394963932</fax>
      <email>rinaldo.bellomo@austin.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Rinaldo Bellomo</name>
      <address>Austin Hospital
Studley Rd
Heidelberg, Vic 3084</address>
      <phone>+61394965992</phone>
      <fax>+61394963932</fax>
      <email>rinaldo.bellomo@austin.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>